This article was originally published in The Tan Sheet
Plaintiffs seek preliminary injunction barring FDA from prohibiting use of antioxidants/cancer risk-reduction health claim until court decides on lawsuit's merits. Plaintiffs will accept "any reasonable short, succinct and accurate disclaimer to guard against potential misleadingness," according to motion filed in D.C. federal court Sept. 14. Emord & Associates asserts FDA's May 4 letter rejecting claim did not evaluate disclaimer language, as ordered in Pearson ruling. FDA's conclusions on ATBC study, other trials are "riddled with profound and basic errors of science," motion adds. Agency rejection cited ATBC data showing higher bladder, stomach cancer incidence with vitamin E (1"The Tan Sheet" May 14, p. 10)
You may also be interested in...
Analyses from the 1994 Alpha-Tocopherol, Beta Carotene intervention trial raise "serious questions" about vitamin E's role in modifying cancer risk, FDA's Center for Food Safety & Applied Nutrition concludes May 4 in rejecting an antioxidant vitamins/cancer health claim.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning